Innoviva, Inc. revenue
Innoviva, Inc.'s revenue was $411m in fiscal 2025, up 14.7% on the year before. Since fiscal 2009 ($24.4m) it has grown at a compound 19.3% a year. Over the last twelve months it was $440m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 24 | 25 | 6 | 5 | 8 | 54 | 134 | 217 | 261 | 261 | 337 | 392 | 331 | 310 | 359 | 411 | 440 |
| Growth on the year before | — | −0.6% | +1.2% | −77.1% | −19.3% | +86.1% | +539.7% | +147.6% | +62.6% | +20.2% | +0.0% | +29.0% | +16.4% | −15.4% | −6.3% | +15.5% | +14.7% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 246 | 296 | 308 | 318 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 79.2% | 82.6% | 74.8% | 72.2% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Royalty | $236M | 57.4% | ▼ 2.2% |
| Products | $172M | 41.8% | ▲ 76.6% |
| Xacduro (part of Products) | $74.4M | 43.2% | ▲ 253.1% |
| Giapreza (part of Products) | $73.6M | 42.8% | ▲ 33.7% |
| Xerava (part of Products) | $23.5M | 13.7% | ▲ 10.0% |
| License and Other Revenue | $2.7M | 0.7% | ▼ 86.0% |
| ZEVTERA | $610,000 | 0.1% | — |
From Innoviva, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Innoviva, Inc. | $440m | 18.8% | 14.9% |
| Ironwood Pharmaceuticals Inc | $389m | 26.2% | -3.1% |
| Xeris Biopharma Holdings, Inc. | $335m | 36.3% | 35.8% |
| Alvotech | $586m | 19.7% | — |
| Evolus, Inc. | $316m | 13.9% | 23.4% |
| Emergent Biosolutions Inc. | $649m | -17.7% | -16.2% |
Compare with peers
- Ironwood Pharmaceuticals Inc revenue
- Xeris Biopharma Holdings, Inc. revenue
- Alvotech revenue
- Evolus, Inc. revenue
- Emergent Biosolutions Inc. revenue
Head to head: INVA vs IRWDINVA vs XERSALVO vs INVA
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies